{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:25:44Z","timestamp":1740176744063,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T00:00:00Z","timestamp":1544486400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40487-018-0088-0","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T18:21:36Z","timestamp":1544552496000},"page":"157-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases"],"prefix":"10.1007","volume":"6","author":[{"given":"Shunji","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Nonomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumasa","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takefumi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ukihide","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Horikoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Igawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Kamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohide","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yokomizo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mana","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Kakehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,11]]},"reference":[{"key":"88_CR1","unstructured":"National Cancer Center (Japan), Cancer Registration and Statistics 2017. http:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/short_pred.html. Accessed 26 Mar 2017."},{"issue":"3","key":"88_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1213755.","journal-title":"N Engl J Med"},{"issue":"7","key":"88_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","volume":"15","author":"O Sartor","year":"2014","unstructured":"Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(14)70183-4.","journal-title":"Lancet Oncol."},{"issue":"8","key":"88_CR4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","volume":"26","author":"S Gillessen","year":"2015","unstructured":"Gillessen S, Omlin A, Attard G, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26(8):1589\u2013604. https:\/\/doi.org\/10.1093\/annonc\/mdv257.","journal-title":"Ann Oncol"},{"issue":"10","key":"88_CR5","first-page":"1","volume":"12","author":"C-C Hsu","year":"2007","unstructured":"Hsu C-C, Sandford BA. The Delphi technique: making sense of consensus. Pract Assess Res Eval. 2007;12(10):1\u20138.","journal-title":"Pract Assess Res Eval."},{"key":"88_CR6","unstructured":"Japanese Urological Association. Clinical guideline for prostate cancer 2012. Bunkyo-ku, Tokyo: Kanehara-Shuppan; 2012. (in Japanese)."},{"issue":"6","key":"88_CR7","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s00120-016-0030-8","volume":"55","author":"C Thomas","year":"2016","unstructured":"Thomas C, B\u00f6gemann M, K\u00f6nig F, et al. Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen: Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel. Urologe A. 2016;55(6):772\u201382. https:\/\/doi.org\/10.1007\/s00120-016-0030-8 (in German).","journal-title":"Urologe A."},{"issue":"1","key":"88_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","volume":"69","author":"P Ost","year":"2016","unstructured":"Ost P, Jereczek-Fossa BA, As NV, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69(1):9\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.004.","journal-title":"Eur Urol"},{"key":"88_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fonc.2015.00101","volume":"5","author":"G Azzam","year":"2015","unstructured":"Azzam G, Lanciano R, Arrigo S, et al. SBRT: an opportunity to improve quality of life for oligometastatic prostate cancer. Front Oncol. 2015;5:101. https:\/\/doi.org\/10.3389\/fonc.2015.00101.","journal-title":"Front Oncol."},{"issue":"10024","key":"88_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(15)01037-5.","journal-title":"Lancet"},{"issue":"2","key":"88_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","volume":"17","author":"CL Vale","year":"2016","unstructured":"Vale CL, Burdett S, Rydzewska LH, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243\u201356. https:\/\/doi.org\/10.1016\/S1470-2045(15)00489-1.","journal-title":"Lancet Oncol."},{"issue":"12","key":"88_CR12","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1007\/s00330-011-2221-4","volume":"21","author":"HL Yang","year":"2011","unstructured":"Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. Eur Radiol. 2011;21(12):2604\u201317. https:\/\/doi.org\/10.1007\/s00330-011-2221-4.","journal-title":"Eur Radiol"},{"issue":"12","key":"88_CR13","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"88_CR14","unstructured":"ASCO Annual Meeting, The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). http:\/\/meetinglibrary.asco.org\/content\/149791-156. Accessed 30 Mar 2017."},{"key":"88_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12885-016-2160-1","volume":"16","author":"K Uemura","year":"2016","unstructured":"Uemura K, Miyoshi Y, Kawahara T, et al. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer. BMC Cancer. 2016;16:109. https:\/\/doi.org\/10.1186\/s12885-016-2160-1.","journal-title":"BMC Cancer."},{"issue":"9","key":"88_CR16","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.ejca.2014.03.010","volume":"50","author":"JM Fitzpatrick","year":"2014","unstructured":"Fitzpatrick JM, Bellmunt J, Fizazi K, et al. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer. 2014;50(9):1617\u201327. https:\/\/doi.org\/10.1016\/j.ejca.2014.03.010.","journal-title":"Eur J Cancer"},{"issue":"4","key":"88_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2015.04.032","volume":"68","author":"F Saad","year":"2015","unstructured":"Saad F, Shore N, Van Poppel H, et al. Impact of bone-targeted therapies in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015;68(4):570\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2015.04.032.","journal-title":"Eur Urol"},{"issue":"8","key":"88_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1503747.","journal-title":"N Engl J Med"},{"issue":"4","key":"88_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, LATITUDE Investigators, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1704174.","journal-title":"N Engl J Med"},{"issue":"4","key":"88_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, STAMPEDE Investigators, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1702900.","journal-title":"N Engl J Med"},{"key":"88_CR21","unstructured":"Janssen Biotech, Inc. Zytiga(r) (Abiraterone acetate). Janssen Biotech, Inc. Horsham, PA. 2018. http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/ZYTIGA-pi.pdf. Accessed 21 Nov 2018."},{"issue":"1","key":"88_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41391-017-0020-y","volume":"21","author":"C Parker","year":"2018","unstructured":"Parker C, Heidenreich A, Nilsson S, Shore N. Current approaches to incorporation of radium-223 in clinical practice. Prostate Cancer Prostatic Dis. 2018;21(1):37\u201347. https:\/\/doi.org\/10.1038\/s41391-017-0020-y.","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"7","key":"88_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/nejmra1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378(7):645\u201357. https:\/\/doi.org\/10.1056\/nejmra1701695.","journal-title":"N Engl J Med."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-018-0088-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-018-0088-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-018-0088-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:58:34Z","timestamp":1724457514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-018-0088-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["88"],"URL":"https:\/\/doi.org\/10.1007\/s40487-018-0088-0","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"type":"print","value":"2366-1070"},{"type":"electronic","value":"2366-1089"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"11 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}